儿童鼻用糖皮质激素安全性的系统综述与荟萃分析
该系统综述与荟萃分析纳入33项研究,评估儿童使用FDA批准及非批准鼻用糖皮质激素(INCS)的安全性。FDA批准途径的INCS总体安全,鼻出血和头痛发生率与安慰剂无显著差异;非FDA批准滴剂可能增加医源性库欣综合征风险,生长速度减慢、HPA轴抑制和视觉改变不常见。
要点
- FDA批准途径的儿童INCS总体安全,鼻出血和头痛与安慰剂无显著差异。
- 非FDA批准INCS滴剂可能增加医源性库欣综合征风险。
- 生长速度减慢、HPA轴抑制和视觉改变在儿童INCS使用中不常见。
核心结论
- FDA批准途径的INCS在儿童中总体安全,非FDA批准滴剂可能增加医源性库欣综合征风险。
- 生长速度减慢、HPA轴抑制和视觉改变因INCS使用而不常见。
研究设计与样本
- 系统综述与荟萃分析,遵循PRISMA指南,检索MEDLINE、PubMed和EMBASE数据库。
- 共纳入33项研究,涵盖鼻喷剂和滴剂等INCS制剂及不良事件。
主要发现
- 未发现皮质醇水平或眼内压持续异常。
- 10项随机试验中3项报告生长速度减慢。
- 生长速度、HPA轴抑制和眼部改变未进行荟萃分析。
临床怎么用
- 儿童使用INCS应优先选择FDA批准途径,避免非FDA批准滴剂以减少医源性库欣综合征风险。
- 临床需关注生长速度、HPA轴和眼部变化,但上述事件不常见。
局限性
- 生长速度、HPA轴抑制和眼部改变因数据不足未进行荟萃分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To address concerns related to the safety profile of both Food and Drug Administration (FDA)-approved and non-FDA-approved intranasal corticosteroid (INCS) use in the pediatric population. DATA SOURCE: Systematic review of MEDLINE, PubMed, and EMBASE databases using comprehensive search strategy, including all INCS formulations and adverse events. The study design was developed using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Additional sources were identified from study references of relevant articles. REVIEW METHODS: A structured literature search was conducted. Extracted data included age, population size, study design, drug (dosage, route, and frequency), presence of hypothalamic-pituitary-adrenal (HPA) axis suppression, ocular symptoms, and growth velocity adverse events. RESULTS: A total of 33 studies met inclusion criteria. The studies included use of INCS as nasal sprays and drops. There were no persistent abnormalities noted in cortisol level or intraocular pressure change. Growth velocity reduction was reported in 3 of 10 randomized trials. Meta-analysis of epistaxis and headache showed no significant difference in the incidence of headache or epistaxis when FDA-approved INCSs were compared to placebo, with a relative risk of 1.12 (95% CI, 0.77-1.63; P = .56) and 0.84 (95% CI, 0.60-1.18; P = .32), respectively. Meta-analysis was not performed for growth velocity, HPA axis suppression, and ocular change. CONCLUSIONS: INCSs in FDA-approved routes of administration are generally safe to use in the pediatric population. Use of non-FDA-approved INCS drops may increase risk of iatrogenic Cushing's syndrome. Growth velocity reduction, HPA axis suppression, and visual changes due to INCS are uncommon.
引用
- Donaldson AM, Choby G, Kim DH, et al. Intranasal Corticosteroid Therapy: Systematic Review and Meta-analysis of Reported Safety and Adverse Effects in Children. Otolaryngol Head Neck Surg. 2020. PMID: 32660332. doi:10.1177/0194599820931454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。